1311148-75-0

Upstream product

• 3510-66-5 2-Bromo-5-methylpyridine 
• 1019780-48-3 5-((1H-imidazol-1-yl)methyl)-2-bromopyridine 
• 22237-12-3 4-methyl-3-amino-phenyl boronic acid 
• 101990-45-8 2-bromo-5-bromomethylpyridine 

Relevant academic research and scientific papers

SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES

The present invention relates to compounds which selectively inhibit CYP11B1. Preferably, the compounds of the present invention do not substantially inhibit CYP11B2. Moreover, the compounds of the present invention do not substantially inhibit CYP17 and/or CYP19, either. Amongst other applications of the compounds of the present invention, they can be used for the treatment of Cushing's syndrome or metabolic disease.

Optimization of the first selective steroid-11β-hydroxylase (CYP11B1) inhibitors for the treatment of cortisol dependent diseases

CYP11B1 is the key enzyme in cortisol biosynthesis, and its inhibition with selective compounds is a promising strategy for the treatment of diseases associated with elevated cortisol levels, such as Cushing's syndrome or metabolic disease. Expanding on a